Magnetic field exposure and liver disease: from current research to future directions.
5 affiliations
- 1Department of Hepatobiliary Surgery, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, Shaanxi, China.
- 2National Local Joint Engineering Research Center for Precision Surgery and Regenerative Medicine, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, Shaanxi, China.
- 3Department of Hepatobiliary Surgery, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, Shaanxi, China. [email protected].
- 4National Local Joint Engineering Research Center for Precision Surgery and Regenerative Medicine, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, Shaanxi, China. [email protected].
- 5Institute of Regenerative and Reconstructive Medicine, Med-X Institute, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710049, Shaanxi, China. [email protected].
Abstract
As both an environmental factor and a therapeutic modality, magnetic field (MF) exposure exerts a significant regulatory effect on liver physiology and pathology. This review systematically synthesizes the current body of evidence regarding the modulatory roles of MFs in liver diseases (LDs) and elaborates on the underlying potential mechanisms. Initially, the biological basis of the interaction between MFs and hepatic tissue is delineated. Subsequently, preclinical evidence is consolidated, which demonstrates that MFs with specific parameter settings exhibit protective or therapeutic potential in experimental models of acute liver injury (ALI), metabolic dysfunction-associated steatotic liver disease (MASLD), hepatic fibrosis (HF), and hepatocellular carcinoma. Accumulating evidence indicates that MFs predominantly exert their regulatory effects by modulating interconnected biological pathways, including iron metabolism, oxidative stress, gut microbiota, as well as cellular autophagy and apoptosis. Collectively, these mechanisms constitute a complex regulatory network that underpins the hepatoprotective effects and potential therapeutic efficacy of MFs. Finally, future perspectives are proposed. While existing evidence remains predominantly preclinical, future research must prioritize the standardization of MF parameters, the further elucidation of underlying mechanisms, and the acceleration of clinical translation. These efforts are essential to definitively establish the therapeutic potential of MFs in the prevention and management of LDs.
Related
- In vivo CAR-T for the treatment of autoimmune diseases: Current progress and future directions
- Regeneration, genetic transformation, and gene editing in Vaccinium species: current progress and future directions
- Environmental monitoring of static magnetic fields around operating high-voltage direct-current transmission facilities in Japan
- EXPOSURE TO EXTREMELY LOW-FREQUENCY MAGNETIC FIELDS IN LOW- AND MIDDLE-INCOME COUNTRIES: AN OVERVIEW
- Extracellular vesicles and Alzheimer’s disease: hotspots, trends, and future directions—a tri-database bibliometric analysis
BibTeX
@article{shen2026magnetic,
title = {{Magnetic field exposure and liver disease: from current research to future directions.}},
author = {Jie Shen and Yajie Li and Long Liu and Xuan Han and Yi Lv},
journal = {Biomedical engineering online},
year = {2026},
month = jul,
doi = {10.1186/s12938-026-01607-5},
url = {https://europepmc.org/article/MED/42919377},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Magnetic field exposure and liver disease: from current research to future directions.
AU - Jie Shen
AU - Yajie Li
AU - Long Liu
AU - Xuan Han
AU - Yi Lv
PY - 2026
DA - 2026/07/01
JO - Biomedical engineering online
DO - 10.1186/s12938-026-01607-5
UR - https://europepmc.org/article/MED/42919377
AB - As both an environmental factor and a therapeutic modality, magnetic field (MF) exposure exerts a significant regulatory effect on liver physiology and pathology. This review systematically synthesizes the current body of evidence regarding the modulatory roles of MFs in liver diseases (LDs) and elaborates on the underlying potential mechanisms. Initially, the biological basis of the interaction between MFs and hepatic tissue is delineated. Subsequently, preclinical evidence is consolidated, which demonstrates that MFs with specific parameter settings exhibit protective or therapeutic potential in experimental models of acute liver injury (ALI), metabolic dysfunction-associated steatotic liver disease (MASLD), hepatic fibrosis (HF), and hepatocellular carcinoma. Accumulating evidence indicates that MFs predominantly exert their regulatory effects by modulating interconnected biological pathways, including iron metabolism, oxidative stress, gut microbiota, as well as cellular autophagy and apoptosis. Collectively, these mechanisms constitute a complex regulatory network that underpins the hepatoprotective effects and potential therapeutic efficacy of MFs. Finally, future perspectives are proposed. While existing evidence remains predominantly preclinical, future research must prioritize the standardization of MF parameters, the further elucidation of underlying mechanisms, and the acceleration of clinical translation. These efforts are essential to definitively establish the therapeutic potential of MFs in the prevention and management of LDs.
SN - 1475-925X
ER -